Zydus Cadila receives USFDA approval for Exemestane tablet

Zydus Cadila has received final USFDA approval to market Exemestane tablets, used for treatment of breast cancer. The drug in the strength of 25 mg will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. According to industry estimates, estimated sale for Exemestane tablets is USD 68.6 million per year.

The company has more than 220 approvals and so far filed over 330 abbreviated new drug applications (ANDAs).

Be the first to comment

Leave a Reply

Your email address will not be published.